The Dedham Group’s Post

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/Uhfc50RRFhb #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

Few drugs have gripped the American public like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace article, I provide commentary on the connection between the GLP-1 and the insulin market. Check out the full article.. https://lnkd.in/eXKA8yEy

The global Burn Injury Treatment market was valued at US$ 2310 million in 2023 and is anticipated to reach US$ 3145.8 million by 2030 witnessing a CAGR of 4.1% during the forecast period 20242030. The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalBurnInjuryTreatmentMarket #BurnInjuryCare #WoundCare #BiologicalProducts #HomeCare #HospitalCare #BurnInjuryRecovery #MarketGrowth #PharmaceuticalMarket #ChemicalDrugMarket

Are the #GLP1 and #insulin markets linked? With strong sales of #weightlossdrugs, questions arise about how crackdowns on #insulinpricing will influence pipeline strategies and if #BigPharma has a social responsibility to produce insulin, even at a loss. https://lnkd.in/dhPdfAPS #diabetes #pharmaceuticals #pharma #drugpricing

https://lnkd.in/g4dT_xg7 Key Insights: • Doxazosin tablets are prescribed for hypertension treatment, aimed at reducing blood pressure • The product will be available for commercial distribution from UniChem’s manufacturing facility located in Goa Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #unichem #approval #fdaapproval #bloodpressure #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

https://lnkd.in/gW-rct8Z Takeaway: The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications. Wall Street’s appetite for all things weight-loss related has been on the rise after a study of Novo Nordisk’s Wegovy showed the medication reduced the risks of heart attacks and strokes. The study results sent shares of drugmaker Eli Lilly & Co. soaring, and it remains the best-performing pharmaceutical stock so far this year in the S&P 500.

We read that the pricing of life-saving pharmaceutical products such as #GLP-1 like #Ozempic and #Wegovy, along with #insulin, is once again under scrutiny. The focus is mostly on the manufacturing costs, using the marginal production cost argument. However, it's important to remember that these products are essential for patients suffering from diabetes and obesity. Companies such as #NovoNordisk understand the importance of ensuring access to these medications to all eligible patients. Let's hope that the focus shifts from mere production costs to funding additional researched in these fields, and to making these medications more affordable for those who need them.

Cost-Effectiveness of Chronic Migraine Medications Assessed A systematic review on the cost-effectiveness of preventive drugs for chronic migraine was conducted. The study compared several drugs, including Onabotulinum toxin A, Eptinezumab, Fremanezumab, Galcanezumab, and Topiramate, to placebo. A Markov model was used to estimate costs and quality-adjusted life years (QALYs) from a UK NHS perspective. The results showed that Topiramate was the most cost-effective option and generated more QALYs than placebo. Eptinezumab was the most costly option but also generated the most QALYs. Further research is recommended to compare these newer, expensive drugs with cheaper oral medications. For more details please click the link! https://lnkd.in/dQiFR75s #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🔷When we think about inflation, we need to give credit to the pharmaceutical industry for displacing every other sector (hospital, ambulatory/physician, etc.,) as the fastest growing cost element of the US healthcare system....this year will not disappoint as a whopper of a year for upward cost pressure. 🔷And which drugs are the biggest contributors? Semaglutide was the top (GLP-1 - officially a T2 diabetes drug but often used for rapid weight loss) adalimumab (a.k.a. Humira and all it's biosimilar cousins) than apixaban (a.k.a. eloquis - an anticoagulant medication) #healthcare #inflation #drugcosts